The in vitro activity of rifampin alone and in combination with 
The in vitro activity of rifampin alone and in combination with oxacillin was determined for 75 Staphylococcus aureus strains (64 susceptible and 11 resistant to oxacillin). Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by broth microdilution; antibiotic combinations were evaluated by microdilution checkerboard and time-kill studies. The 90% MIC of rifampin was <0.015 jig/ml after both 24 and 48 h of incubation. The 90% MBC of rifampin was s2.0 ,ug/ml on subculture at 24 h of incubation and c0. 5 ,ug/ml on subculture at 48 h. MIC checkerboards with oxacillin-susceptible strains revealed an additive or indifferent effect in 35 strains (55%) and antagonism in 29 strains (45%). MBC checkerboards performed by subculture at 24 h demonstrated antagonism for all but one of the oxacillin-susceptible strains, with sub-MBCs of rifampin impairing the bactericidal activity of oxacillin. MBC checkerboards performed by 48-h subculture revealed antagonism with 37 strains (58%); in 26 additional strains (40%), a synergistic, additive, or indifferent effect was observed at low antibiotic concentrations, but antagonism was seen at higher concentrations. Time-kill studies tended to show indifference rather than antagonism with oxacillin plus rifampin. In checkerboards performed with oxacillinresistant strains, the addition of rifampin did not improve oxacillin inhibitory or bactericidal activity to a clinically significant extent; however, the addition of oxacillin improved the bactericidal activity of rifampin at easily achievable serum concentrations.
Rifampin in combination with other antibiotics, including semisynthetic penicillins, vancomycin, and gentamicin, has been advocated for treatment of serious staphylococcal infections unresponsive to conventional single-drug therapy (2, 5, 7, 12, 14, 16) . It has been noted that rifampin has impressive in vitro inhibitory activity against staphylococci (1, 10, 18, 23) , reaches potentially therapeutic concentrations in a wide range of tissue and body fluids (including cerebrospinal fluid) (3, 20, 21) , and kills bacteria sequestered within leukocytes (13) . Rifampinresistant staphylococci emerge rapidly when rifampin is used alone, necessitating the administration of an additional antibiotic with antistaphylococcal activity (4, 10, 12) .
Although the use of rifampin in combination with other agents is buttressed by persuasive theoretical considerations as well as by in vitro and animal model experiments (12, 16) and anecdotal clinical reports (2, 5, 7, 14) , some studies have suggested that the bactericidal activity of rifampin against staphylococci is not as impressive as its inhibitory activity (10, 25) . Moreover, when rifampin has been combined with P-lactam antibiotics (26) (Table 2) . MBCs were considerably higher than MICs when subcultures were performed after 24 h of incubation (Table 2) , with a 90% MBC of s2.0 p.g/ml. The rifampin MBC was at least 32 tube dilutions greater than the MIC in 56 of 64 (88%) oxacillin-susceptible strains and in all 11 of the oxacillin-resistant strains. Improved bactericidal activity was observed when subcultures were performed after 48 h of incubation; the 90% MBC for rifampin fell to s0.5 ,ug/ml, and the MBC/MIC ratio was .32 for only 16% of the oxacillin-susceptible strains and 82% of the oxacillin-resistant strains. All strains were killed by concentrations of rifampin which are easily achieved in serum with standard oral dosages (8) . b In 18 strains (28%), an additive or indifferent effect was seen at low rifampin and oxacillin concentrations, but antagonism was observed at higher concentrations. In 8 strains (12%), synergy was seen at low concentrations, whereas antagonism was observed at higher concentrations.
Checkerboard testing. MIC checkerboard testing with oxacillin-susceptible strains revealed an additive effect in 25 (39%), an indifferent effect in 10 (16%), and antagonism in 29 (45%) ( Table  3) . MBC checkerboards showed antagonism with all of the oxacillin-susceptible strains when subcultures were performed after 24 h of incubation. For 50 of the 64 strains (78%), there was little or no impact on killing by rifampin with changes in the concentration of oxacillin, but sub-MBC concentrations of rifampin apparently antagonized the bactericidal activity of oxacillin (representative checkerboard, Fig. 1 ). When subcultures were performed after 48 h of incubation, antagonism was observed with all but one of the oxacillin-susceptible strains. In 26 of the strains (40%), a synergistic, additive, or indifferent effect was seen at low antibiotic concentrations, but antagonism was seen at higher concentrations (Table 3; representative checkerboard, Fig. 2 ). This effect is consistent with a hetero-additive isobol for homodynamic drugs described by Loewe (11) . The improved bactericidal activity of rifampin at 48 h was evident in the presence of low concentrations of oxacillin. Staphylococci isolated on a 48-h subculture of wells containing the rifampin MBC and an oxacillin concentration greater than the oxaciflin MBC had not changed in their susceptibilities to either oxacillin or rifampin alone.
It was not possible to accurately classify the results of checkerboard testing with oxacillinresistant strains, since oxacillin concentrations in the microdilution plates were not high enough to detect a 2 tube dilution reduction in oxacillin MICs and MBCs. However, in no case did the addition of rifampin at concentrations less than the rifampin MIC inhibit growth of staphylococci in wells containing s2 ,ug of oxacillin per ml, the breakpoint for oxacillin susceptibility. In addition, sub-MBCs of rifampin did not produce killing in wells containing 2 p,g of oxacillin per ml (Fig. 3) . Oxacillin produced no change in the inhibitory activity of rifampin but did improve rifampin bactericidal activity by 1 to 2 tube dilutions (Fig. 3) .
Time-kill studies. The combination of rifampin and oxacillin at their MBCs produced an indifferent effect with oxacillin-susceptible S. aureus strains. When the rifampin MBC was combined with oxacillin at 10 times its MBC, killing was not as rapid as with oxacillin alone (representative study, Fig. 4) . However, this effect on killing was not sufficient to satisfy the criterion for antagonism.
DISCUSSION
The combination of rifampin plus a bactericidal cell wall-active antibiotic has produced striking improvement in some patients with serious staphylococcal disease (2, 5, 14) , but , Oxacillin at 5.0 ,ug/ml; ---, rifampin at 1.0 pgfml;n, oxacillin at 5.0 ,ig/ml plus rifampin at 1.0 ,ug/ml; -, control. In the present study, all S. aureus strains were inhibited by very low concentrations of rifampin, but killing required higher concentrations. For the majority of strains, the rifampin MBC was at least 32-fold greater than the MIC. However, most strains were killed by concentrations of rifampin well below peak achievable serum levels (8) .
MIC checkerboards demonstrated an additive or indifferent effect for most strains and antagonism for the remainder; synergy was not observed. Antagonism was generally observed in MBC checkerboards when subcultures were performed at either 24 or 48 h. Examination of the MBC checkerboards revealed that subMBCs of rifampin nullified the bactericidal activity of oxacillin. On the other hand, killing was achieved by rifampin concentrations near the MBC, regardless of the concentration of oxacillin present in the microdilution wells. The mechanism of the antagonism we observed is unknown, but it is likely that rifampin concentrations which are sufficient to inhibit bacterial cell growth but not to kill staphylococci interfere with the bactericidal effect of cell wall agents like oxacillin which act on growing bacteria (6) .
As discouraging as these in vitro results may seem, they in no way imply that rifampin in combination with oxacillin would be ineffective therapy for serious staphylococcal disease. Although rifampin antagonized the bactericidal activity of oxacillin, the majority of strains were killed in the presence of oxacillin by rifampin concentrations achievable in serum. Moreover, oxacillin would be expected to prevent outgrowth of rifampin-resistant subpopulations when treating infections associated with higher concentrations of staphylococci (12) . In addition, rifampin penetrates tissues exceptionally well (20) and can kill staphylococci sequestered within leukocytes (13) ; these are potentially important therapeutic advantages which were not addressed by our studies. In view of our findings, however, clinical evaluation of rifampin and oxacillin for the treatment of S. aureus infections should proceed with caution.
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